Recursion Pharmaceuticals (NASDAQ: RXRX), a small-cap biotech company, has one claim to fame: It currently owns the largest ...
Here is the AI research roadmap for 2026: how agents that learn, self-correct, and simulate the real world will redefine ...
I played these 25 cards the most and built so many decks around them — or at least dreamed how they might function in the ...
The year 2025 marked a major leap for AI in health care, with breakthroughs in drug discovery, diagnostics, genomics and ...
Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a ...
Nostalgia has become one of the most powerful currencies in Bollywood’s contemporary marketing apparatus. The recycling of ...
Former Google CEO Eric Schmidt believes AI's rapid advancement, already handling 10-20% of programming tasks, signals the end ...
One of the key learning outcomes of university education in general, and liberal arts programmes, in particular, is that ...
Introduction Application of artificial intelligence (AI) tools in the healthcare setting gains importance especially in the domain of disease diagnosis. Numerous studies have tried to explore AI in ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
His job is to reimagine the future of drugmaking using that similarly trendy branch of computer science, artificial ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback